Molecular Pharmacology and Pathology Program, Department of Pathology and Bosch Institute, University of Sydney, Sydney, New South Wales 2006, Australia.
Molecular Pharmacology and Pathology Program, Department of Pathology and Bosch Institute, University of Sydney, Sydney, New South Wales 2006, Australia; Department of Pathology and Biological Responses, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
Biochim Biophys Acta Mol Basis Dis. 2020 May 1;1866(5):165657. doi: 10.1016/j.bbadis.2019.165657. Epub 2020 Jan 2.
Upon activation, the 5'-adenosine monophosphate-activated protein kinase (AMPK) increases catabolism, while inhibiting anabolism. The anti-cancer agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT), activates AMPK in multiple tumor cell-types (Biochim. Biophys Acta 2016;1863:2916-2933). This acts as an initial cell "rescue response" after iron-depletion mediated by Dp44mT. Considering Dp44mT-mediated AMPK activation, the role of AMPK on Dp44mT cytotoxicity was examined. Dp44mT increased the p-AMPK/AMPK ratio in multiple tumor cell-types over short (24 h) and longer (72 h) incubations. Notably, Dp44mT was more effective in inhibiting tumor cell proliferation after AMPK silencing, potentially due to the loss of AMPK-mediated metabolic plasticity that protects cells against Dp44mT cytotoxicity. The silencing of AMPK-increased cellular cholesterol and stabilized lysosomes against Dp44mT-mediated lysosomal membrane permeabilization. This was substantiated by studies demonstrating that the cholesterol-depleting agent, methyl-β-cyclodextrin (MβCD), restores Dp44mT-mediated lysosomal membrane permeabilization in AMPK silenced cells. The increased levels of cholesterol after AMPK silencing were independent of the ability of AMPK to inhibit the rate-limiting step of cholesterol synthesis via the inactivating phosphorylation of 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR) at Ser872. In fact, Dp44mT did not increase phosphorylation of HMGCR at (Ser872), but decreased total HMGCR expression similarly in both the presence or absence of AMPK silencing. Dp44mT was demonstrated to increase autophagic initiation after AMPK silencing via an AMPK- and Beclin-1-independent mechanism. Further, there was increased cleaved caspase 3 and cleaved PARP after incubation of AMPK silenced cells with Dp44mT. Overall, AMPK silencing promotes Dp44mT anti-proliferative activity, suggesting a role for AMPK in rescuing its cytotoxicity by inhibiting autophagy and also apoptosis.
在激活后,5'-腺苷一磷酸激活蛋白激酶(AMPK)增加分解代谢,同时抑制合成代谢。抗癌剂二吡啶酮 4,4-二甲基-3-硫代缩氨基脲(Dp44mT)可激活多种肿瘤细胞类型中的 AMPK(生物化学与生物物理学报 2016 年;1863:2916-2933)。这是 Dp44mT 介导的铁耗竭后细胞的初始“挽救反应”。考虑到 Dp44mT 介导的 AMPK 激活,研究了 AMPK 对 Dp44mT 细胞毒性的作用。Dp44mT 在多种肿瘤细胞类型中在短时间(24 小时)和长时间(72 小时)孵育后增加 p-AMPK/AMPK 比值。值得注意的是,在 AMPK 沉默后,Dp44mT 更有效地抑制肿瘤细胞增殖,这可能是由于 AMPK 介导的代谢灵活性丧失,这种灵活性保护细胞免受 Dp44mT 细胞毒性的影响。AMPK 沉默增加了细胞胆固醇,并稳定溶酶体,防止 Dp44mT 介导的溶酶体膜通透性增加。这一点得到了研究的证实,该研究表明胆固醇耗竭剂甲基-β-环糊精(MβCD)可恢复 AMPK 沉默细胞中 Dp44mT 介导的溶酶体膜通透性。AMPK 沉默后胆固醇水平的增加与 AMPK 通过使 3-羟基-3-甲基戊二酰辅酶 A 还原酶(HMGCR)在 Ser872 处失活磷酸化来抑制胆固醇合成的限速步骤的能力无关。事实上,Dp44mT 并没有增加 HMGCR 在(Ser872)处的磷酸化,但在 AMPK 沉默存在或不存在的情况下,总 HMGCR 表达同样减少。研究表明,Dp44mT 在沉默 AMPK 后通过 AMPK 和 Beclin-1 独立的机制增加自噬起始。此外,在用 Dp44mT 孵育 AMPK 沉默的细胞后,有更多的裂解的 caspase 3 和裂解的 PARP。总的来说,AMPK 沉默促进了 Dp44mT 的抗增殖活性,这表明 AMPK 通过抑制自噬和凋亡来挽救其细胞毒性的作用。